Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Bussel

Showing results (1-10 of 262) with videos related to

Pageof 27
Sort By:
British Journal of Haematology|November 21, 2022
Why should intramuscular anti-D be different from intravenous anti-D?James B Bussel
Oncology (Williston Park, N.Y.)|January 2, 2010
Update on eltrombopag for ITPJames B Bussel
Thrombosis and Haemostasis|January 17, 2003
Another interaction of the FcR system with IVIGJames B Bussel
Best Practice & Research. Clinical Haematology|December 3, 2014
The new thrombopoietic agenda: impact on leukemias and MDSJames B Bussel
Seminars in Hematology|February 28, 2009
The changing landscape of secondary ITP: introductionJames B Bussel
American Journal of Hematology|October 17, 2020
Early combination treatment of immune thrombocytopenia: Is this the way?James B Bussel
Transfusion|January 13, 2016
What do we know about intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia?James B Bussel
Transfusion|January 9, 2007
Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigensJames B Bussel
American Journal of Perinatology|January 3, 2004
Fetal and neonatal cytopenias: what have we learned?James B Bussel
Hematology/Oncology Clinics of North America|November 26, 2009
Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treatJames B Bussel
Pageof 27

Showing results (1-10 of 262) with videos related to

Sort By:
Pageof 27
British Journal of Haematology|November 21, 2022
Why should intramuscular anti-D be different from intravenous anti-D?James B Bussel
Oncology (Williston Park, N.Y.)|January 2, 2010
Update on eltrombopag for ITPJames B Bussel
Thrombosis and Haemostasis|January 17, 2003
Another interaction of the FcR system with IVIGJames B Bussel
Best Practice & Research. Clinical Haematology|December 3, 2014
The new thrombopoietic agenda: impact on leukemias and MDSJames B Bussel
Seminars in Hematology|February 28, 2009
The changing landscape of secondary ITP: introductionJames B Bussel
American Journal of Hematology|October 17, 2020
Early combination treatment of immune thrombocytopenia: Is this the way?James B Bussel
Transfusion|January 13, 2016
What do we know about intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia?James B Bussel
Transfusion|January 9, 2007
Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigensJames B Bussel
American Journal of Perinatology|January 3, 2004
Fetal and neonatal cytopenias: what have we learned?James B Bussel
Hematology/Oncology Clinics of North America|November 26, 2009
Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treatJames B Bussel
Pageof 27